Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
María‐Teresa Cedena(Hospital Universitario 12 De Octubre), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Jesús María Hernández‐Rivas(Universidad de Salamanca), Guillermo Sanz(Instituto de Salud Carlos III), Fernando Ramos(Hospital de León), Esther Onecha(Hospital Universitario 12 De Octubre), María Díez‐Campelo(Complejo Hospitalario de Salamanca), Esperanza Such(Leitat Technological Center), Alejandro Lucía(Instituto de Salud Carlos III), Rosa Ayala(Hospital Universitario 12 De Octubre), Alejandro Santos‐Lozano(Universidad Europea Miguel de Cervantes), María Abáigar(Universidad de Salamanca), José Cervera(Hospital Universitari i Politècnic La Fe), Inmaculada Rapado(Wellcome Sanger Institute)
Cited by 1
Related Papers
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963
Non-coding recurrent mutations in chronic lymphocytic leukaemia
|Nature|2015|851